Mirna Therapeutics, Inc. Appoints Lawrence M. Alleva To Its Board Of Directors

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Mirna Therapeutics, a clinical-stage biotechnology company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the appointment of Lawrence M. Alleva, a former partner with PricewaterhouseCoopers LLP, as an outside director to its Board of Directors.

“We are excited to have Larry join our distinguished group of directors. As a finance professional with more than 30 years of experience in technology industries, his expertise and guidance will be invaluable to Mirna as we continue to build our company along with driving forward the clinical program for MRX34, the first microRNA Replacement Therapy in clinical trials,” said Dr. Paul Lammers, President and Chief Executive Officer of Mirna.

Help employers find you! Check out all the jobs and post your resume.

Back to news